Ablynx outlines next steps, as AbbVie pulls out of vobarilizumab option

20 October 2016

Belgian drug developer Ablynx (Euronext Brussels: ABLX) has revealed that its partner, USA-based AbbVie (NYSE: ABBV), has decided not to exercise its option and license on vobarilizumab for rheumatoid arthritis under their 2013 collaboration,

The collaboration included a $175 million upfront payment and was worth a further $665 million in milestones. The news sent Ablynx’ shares tumbling 18.4% to 8.90 euros by mid-afternoon today.

As a result Ablynx said today that it will initiate the processes for end-of-Phase II and scientific advice meetings with the regulators in the USA and Europe (Food and Drug Administration and European Medicines Agency and EMA) for its anti-interleukin (IL)-6R Nanobody, vobarilizumab, as part of the preparations to start Phase III clinical development in patients with rheumatoid arthritis (RA).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK